MCID: TXC002
MIFTS: 57

Toxic Encephalopathy

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Toxic Encephalopathy

MalaCards integrated aliases for Toxic Encephalopathy:

Name: Toxic Encephalopathy 12 54 15 17
Neurotoxicity Syndromes 77 54 45
Neurotoxicity 12 55 15
Neurotoxicity Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3602
MeSH 45 D020258
NCIt 51 C27961
SNOMED-CT 69 19466003
ICD10 34 G92
UMLS 74 C0235032

Summaries for Toxic Encephalopathy

NINDS : 55 Neurotoxicity occurs when the exposure to natural or manmade toxic substances (neurotoxicants) alters the normal activity of the nervous system. This can eventually disrupt or even kill neurons, key cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from exposure to substances used in chemotherapy, radiation treatment, drug therapies, and organ transplants, as well as exposure to heavy metals such as lead and mercury, certain foods and food additives, pesticides, industrial and/or cleaning solvents, cosmetics, and some naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness; loss of memory, vision, and/or intellect; headache; cognitive and behavioral problems; and sexual dysfunction. Individuals with certain disorders may be especially vulnerable to neurotoxicants.

MalaCards based summary : Toxic Encephalopathy, also known as neurotoxicity syndromes, is related to alzheimer disease and ischemia. An important gene associated with Toxic Encephalopathy is HMOX1 (Heme Oxygenase 1), and among its related pathways/superpathways are Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Oxaliplatin and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and b cells, and related phenotypes are Decreased caspase 3/7 activity and behavior/neurological

Disease Ontology : 12 A nervous system disease that results from exposure to neurotoxicants and is characterized by an altered mental status, memory loss, and visual problems.

Wikipedia : 77 Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an... more...

Related Diseases for Toxic Encephalopathy

Diseases related to Toxic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
# Related Disease Score Top Affiliating Genes
1 alzheimer disease 31.4 ACHE APP BDNF CASP3 CYCS GRIN2A
2 ischemia 30.6 APP CASP3 CYCS HMOX1
3 status epilepticus 30.4 BDNF CASP3 GRIN2B
4 pheochromocytoma 30.3 CASP3 MAOB NGF TH
5 hearing loss, noise-induced 30.2 GSTM1 TH
6 peripheral nervous system disease 30.2 ACHE NGF PNPLA6
7 major depressive disorder 30.0 ABCB1 BDNF GRIN2B SLC6A3
8 cocaine abuse 30.0 SLC18A2 SLC6A3 SNCA
9 huntington disease 30.0 BDNF CASP3 CYCS GRIN2A GRIN2B PRNP
10 frontotemporal dementia 30.0 ACHE APP PRNP SNCA
11 akinetic mutism 29.9 PRNP SLC6A3
12 bipolar disorder 29.9 BDNF SLC18A2 SLC6A3 TH
13 fetal alcohol spectrum disorder 29.9 BDNF GRIN2A GRIN2B
14 alcohol dependence 29.8 BDNF GRIN2A GRIN2B MAOB SLC6A3
15 amyotrophic lateral sclerosis 1 29.8 APP BDNF CASP3 CYCS MAOB NGF
16 mood disorder 29.7 BDNF MAOB SLC18A2 TH
17 movement disease 29.7 SLC18A2 SLC6A3 SNCA TH
18 disease of mental health 29.6 APP BDNF GRIN2A GRIN2B SLC6A3 SNCA
19 aphasia 29.5 APP BDNF GRIN2A PRNP SNCA
20 dementia 29.4 ACHE APP BDNF ITIH4 PRNP SLC6A3
21 schizophrenia 29.2 BDNF GRIN2A GRIN2B MAOB SLC18A2 SLC6A3
22 parkinson disease, late-onset 29.0 ACHE APP BDNF CASP3 CYCS HMOX1
23 central nervous system disease 28.6 APP BDNF CASP3 HMOX1 MAOB NGF
24 nervous system disease 28.6 ACHE APP BDNF CASP3 GRIN2B MAOB
25 phenylketonuria 11.3
26 hepatic encephalopathy 11.3
27 fetal methylmercury syndrome 11.3
28 hypermanganesemia with dystonia 11.2
29 alzheimer disease 2 11.0
30 alzheimer disease mitochondrial 11.0
31 alzheimer disease 4 11.0
32 alzheimer disease 3 11.0
33 alzheimer disease 9 11.0
34 alzheimer disease 18 11.0
35 alzheimer disease 19 11.0
36 kernicterus 11.0
37 hyperbetaalaninemia 11.0
38 chronic bilirubin encephalopathy 11.0
39 encephalopathy 10.8
40 neuroblastoma 1 10.4
41 neonatal hypoxic and ischemic brain injury 10.4 BDNF TH
42 tendinosis 10.3 ACHE BDNF TH
43 bile acid synthesis defect, congenital, 1 10.3 GRIN2A GRIN2B
44 substance dependence 10.3 BDNF GSTM1 SLC6A3
45 alpha thalassemia-intellectual disability syndrome type 1 10.3 BDNF GRIN2A TH
46 epilepsy, focal, with speech disorder and with or without mental retardation 10.3 GRIN2A GRIN2B
47 valproate embryopathy 10.3 BDNF GRIN2A GRIN2B
48 rem sleep behavior disorder 10.3 ACHE SLC6A3 SNCA
49 neuropathy 10.3
50 multiple system atrophy 1 10.3 SLC6A3 SNCA TH

Graphical network of the top 20 diseases related to Toxic Encephalopathy:



Diseases related to Toxic Encephalopathy

Symptoms & Phenotypes for Toxic Encephalopathy

GenomeRNAi Phenotypes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased caspase 3/7 activity GR00318-A 8.92 APP CASP3 GRIN2A GRIN2B

MGI Mouse Phenotypes related to Toxic Encephalopathy:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 ABCB1 ABCG2 ACHE APP BDNF CASP3
2 cellular MP:0005384 10.36 ABCG2 APP BDNF CASP3 CYCS HMOX1
3 homeostasis/metabolism MP:0005376 10.36 ABCB1 ABCG2 ACHE APP BDNF CASP3
4 growth/size/body region MP:0005378 10.35 ABCB1 ACHE APP BDNF CASP3 CYCS
5 mortality/aging MP:0010768 10.28 ABCB1 ACHE APP BDNF CASP3 CYCS
6 nervous system MP:0003631 10.25 ABCB1 ABCG2 ACHE APP BDNF CASP3
7 cardiovascular system MP:0005385 10.22 ABCB1 APP CASP3 CYCS HMOX1 NGF
8 integument MP:0010771 10.17 ABCG2 APP BDNF CASP3 GRIN2A NGF
9 endocrine/exocrine gland MP:0005379 10.15 ABCB1 BDNF CASP3 CYCS HMOX1 PRNP
10 muscle MP:0005369 9.97 ACHE APP CASP3 HMOX1 NGF PRNP
11 no phenotypic analysis MP:0003012 9.96 ABCB1 ACHE APP BDNF CASP3 GRIN2B
12 normal MP:0002873 9.81 ABCG2 APP BDNF ITIH4 NGF PRNP
13 reproductive system MP:0005389 9.61 ABCB1 ACHE APP BDNF CASP3 HMOX1
14 taste/olfaction MP:0005394 9.02 BDNF CASP3 SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Toxic Encephalopathy

Drugs for Toxic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 570)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
4
Fluorouracil Approved Phase 4,Phase 2,Phase 3 51-21-8 3385
5
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
6
Colistin Approved Phase 4 1066-17-7, 1264-72-8 5311054
7
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
8
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
9
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 113775-47-6 5311068 68602
10
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
11
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
12
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
13
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 6473866 445643 439492
14
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 38396-39-3, 2180-92-9 2474
15
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 439-14-5 3016
16
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
17
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
18
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
19
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
20
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
21
Levobupivacaine Approved, Investigational Phase 4,Not Applicable 27262-47-1 92253
22
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206
23
Desflurane Approved Phase 4 57041-67-5 42113
24
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
25
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
27
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
28
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
29
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
30
Mycophenolic acid Approved Phase 4,Phase 2,Not Applicable 24280-93-1 446541
31
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
32
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
33
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
34
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
35
Levetiracetam Approved, Investigational Phase 4,Phase 2 102767-28-2 441341
36
Cobicistat Approved Phase 4,Not Applicable 1004316-88-4
37
Tenofovir Approved, Experimental, Investigational Phase 4,Not Applicable 147127-20-6 464205
38
Emtricitabine Approved, Investigational Phase 4,Not Applicable 143491-57-0 60877
39
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
40
alemtuzumab Approved, Investigational Phase 4,Phase 1,Phase 2 216503-57-0
41
Lorazepam Approved Phase 4,Not Applicable 846-49-1 3958
42
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
43
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
44
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
45
Abacavir Approved, Investigational Phase 4 136470-78-5 441300 65140
46
Dolutegravir Approved Phase 4 1051375-16-6 54726191
47
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
48
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
49
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
50
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 46835353 5284616 6436030

Interventional clinical trials:

(show top 50) (show all 511)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
3 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
4 Colistin Pharmacokinetics in Continuous Renal Replacement Therapy Unknown status NCT02081560 Phase 4 Colistin
5 Lipids and Neurological Complications in Liver Transplantation Unknown status NCT02544919 Phase 4 SMOF lipid (SMOFLIPID) pre treatment
6 Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria Unknown status NCT02328183 Phase 4 Polymyxin B
7 Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán Completed NCT03877120 Phase 4 Dexmedetomidine 0.004 MG/ML;Diazepam Injectable Solution
8 BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients Completed NCT02051062 Phase 4
9 Cognitive and Behavioral Effects of Lacosamide Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
10 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4 Targin
11 Thermal QST for Interscale Block Evaluation Completed NCT02271867 Phase 4
12 Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4 Desflurane;Sevoflurane
13 Taste, Smell and Chemotherapy (TASTY) Completed NCT01641172 Phase 4
14 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
15 Steroid Free Immunosuppression in Liver Transplantation Completed NCT00296244 Phase 4 Steroids;Basiliximab;Tacrolimus;Enteric-coated Mycophenolic acid (EC-MPA)
16 Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
17 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
18 A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c) Recruiting NCT03685500 Phase 4 Symtuza® (TAF/FTC/DRV/c);ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)
19 Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) Recruiting NCT03163277 Phase 4 emtricitabine, darunavir/cobicistat, maraviroc
20 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
21 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Recruiting NCT02334722 Phase 4 Levetiracetam extended release
22 Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation Recruiting NCT03076151 Phase 4 Tacrolimus monohydrate (ADOPORT®)
23 IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy Recruiting NCT02918409 Phase 4 Colistin;Tobramycin
24 A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Active, not recruiting NCT03067285 Phase 4 ELV/COBI/FTC/TAF;DTG/3TC/ABC + ELV/COBI/FTC/TAF
25 PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Active, not recruiting NCT02864030 Phase 4 ERIBULIN MESYLATE
26 Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction Active, not recruiting NCT01935128 Phase 4 Arm 1 Everolimus/Reduced dose tacrolimus
27 Envarsus Neurotoxicity Burden in Liver Transplant Patients Not yet recruiting NCT03823768 Phase 4 Envarsus;Tacrolimus Immediate release
28 Analgesic Efficacy of Two Doses of Dexmedetomidine as Adjuncts to Lidocaine for Intravenous Regional Anesthesia Not yet recruiting NCT03399474 Phase 4 Dexmedetomidine Injection 0.25 ug/kg;Lidocaine;Nalbuphine;Paracetamol;Diclofenac sodium (Voltaren®);Dexmedetomidine Injection 0.5ug/kg
29 L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer Terminated NCT00754767 Phase 4 L-carnitine L-tartrate
30 Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
31 CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer Terminated NCT00129870 Phase 4 oxaliplatin
32 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 MMF (Cellcept);placebo
33 Pain Management After Total Shoulder Arthroplasty Terminated NCT03219983 Phase 4 Ropivacaine;liposomal bupivacaine
34 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
35 Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer Unknown status NCT02024438 Phase 3 monosialotetrahexosylganglioside Sodium
36 Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC Unknown status NCT02024412 Phase 3 monosialotetrahexosylganglioside Sodium
37 Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients Unknown status NCT01882621 Phase 3 Monosialoganglioside(GM1);normal saline
38 Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients Unknown status NCT00872352 Phase 3
39 Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain Unknown status NCT02084355 Phase 3 oral oxycodone;oral hydromorphone;fentanyl patch
40 The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy Unknown status NCT02024191 Phase 3
41 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Unknown status NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
42 Dexmedetomidine Versus Magnesium Sulphate for Caesarean Delivery Unknown status NCT03067896 Phase 3 Bupivacaine;Dexmedetomidine;Magnesium Sulfate
43 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00274872 Phase 2, Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
44 Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer Unknown status NCT00058474 Phase 3 capecitabine;fluorouracil;oxaliplatin
45 Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Completed NCT00305188 Phase 3 Xaliproden (SR57746A);Placebo;Oxaliplatin;5-Fluorouracil;Leucovorin
46 XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy Completed NCT00272051 Phase 3 SR57746A
47 Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
48 Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer Completed NCT02468739 Phase 3 Ganglioside-monosialic acid;placebo
49 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin
50 Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity Completed NCT01087658 Phase 3 Glutamine;Calcium and Magnesium

Search NIH Clinical Center for Toxic Encephalopathy

Cochrane evidence based reviews: neurotoxicity syndromes

Genetic Tests for Toxic Encephalopathy

Anatomical Context for Toxic Encephalopathy

MalaCards organs/tissues related to Toxic Encephalopathy:

42
Brain, T Cells, B Cells, Testes, Skin, Colon, Kidney

Publications for Toxic Encephalopathy

Articles related to Toxic Encephalopathy:

(show top 50) (show all 141)
# Title Authors Year
1
Diagnosing solvent-induced chronic toxic encephalopathy: the effect of underperformance in neuropsychological testing. ( 31082289 )
2019
2
Toxic Encephalopathy After Relapsed Indolent Non-Hodgkin's Lymphoma Following Abrupt Discontinuation of Idelalisib (ZYDELIG®). ( 31016071 )
2019
3
The clinical and pathological features of toxic encephalopathy caused by occupational 1,2-dichloroethane exposure. ( 31027082 )
2019
4
Acute toxic encephalopathy induced by occupational exposure to 1,2-dichloropropane. ( 29973469 )
2018
5
An aggravated return-to-work case of organic solvent induced chronic toxic encephalopathy. ( 29719722 )
2018
6
An easily overlooked cause of toxic encephalopathy: methylene blue in a patient on an SSRI. ( 28748330 )
2018
7
Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment. ( 29121830 )
2017
8
Routine fruit washing to prevent acute toxic encephalopathy. ( 28807178 )
2017
9
Routine fruit washing to prevent acute toxic encephalopathy - Authors' reply. ( 28807179 )
2017
10
Association of acute toxic encephalopathy with litchi consumption in an outbreak in Muzaffarpur, India, 2014: a case-control study. ( 28153514 )
2017
11
Myoclonic seizure prior to diagnosis of chronic toxic encephalopathy: a case report. ( 28173825 )
2017
12
Early Non-invasive Detection of Acute 1,2-Dichloroethane-induced Toxic Encephalopathy in Rats. ( 27815462 )
2016
13
Poster 349 Toxic Encephalopathy and Rash Resulting from Paradichlorobenzene Inhalation: A Case Report. ( 27673102 )
2016
14
Odorless inhalant toxic encephalopathy in developing countries household: Gas geyser syndrome. ( 27114653 )
2016
15
The effect of hemoperfusion on patients with toxic encephalopathy induced by silkworm chrysalis ingestion. ( 26610794 )
2016
16
Capecitabine: toxic encephalopathy. ( 26688902 )
2015
17
Toxic encephalopathy after exposure to azacitidine. ( 25224457 )
2015
18
A case of life-threatening acute kidney injury with toxic encephalopathy caused by Dioscorea quinqueloba. ( 25510780 )
2015
19
1,2-Dichloroethane-induced toxic encephalopathy: a case series with morphological investigations. ( 25743226 )
2015
20
Toxic encephalopathy due to paradichlorobenzene toxicity: a case report and review of imaging characteristics. ( 26388394 )
2015
21
Neem oil poisoning as a cause of toxic encephalopathy in an infant. ( 24522945 )
2014
22
Toxic encephalopathy due to colchicine--Gloriosa superba poisoning. ( 24591648 )
2014
23
Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology. ( 24631316 )
2014
24
Prolonged Toxic Encephalopathy following Accidental 4-Aminopyridine Overdose. ( 24822136 )
2014
25
L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. ( 23961306 )
2013
26
Neem oil poisoning: Case report of an adult with toxic encephalopathy. ( 24339648 )
2013
27
MRI brain in monohalomethane toxic encephalopathy: A case report. ( 24347845 )
2013
28
Ethylene glycol toxic encephalopathy. ( 24347968 )
2013
29
Lethal toxic encephalopathy due to childhood shigellosis or Ekiri syndrome. ( 22177366 )
2012
30
Toxic encephalopathy. ( 22362126 )
2012
31
Toxic encephalopathy. ( 23251840 )
2012
32
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( 20926454 )
2011
33
Establishment of a poisoned animal model of toxic encephalopathy induced by 1,2-dichloroethane. ( 21329570 )
2011
34
Toxic encephalopathy. ( 21590623 )
2011
35
Toxic encephalopathy caused by occupational exposure to 1, 2-Dichloroethane. ( 20163807 )
2010
36
An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? ( 19402572 )
2009
37
Acute toxic encephalopathy due to the ingestion of Rhus extract. ( 19570681 )
2009
38
High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. ( 19596561 )
2009
39
Toxic encephalopathy after taking dried seeds of Datura stramonium in two elderly subjects. ( 19702945 )
2009
40
Margosa (Kohomba) oil induced toxic encephalopathy following home remedy for intestinal worms. ( 20052860 )
2009
41
[Star fruit (Averrhoa carambola) toxic encephalopathy]. ( 18755486 )
2009
42
Psychosocial and cognitive rehabilitation of patients with solvent-induced chronic toxic encephalopathy: a randomised controlled study. ( 18560254 )
2008
43
Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. ( 19031955 )
2008
44
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. ( 17938643 )
2008
45
Chronic toxic encephalopathy caused by occupational solvent exposure. ( 18409195 )
2008
46
Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. ( 17762322 )
2007
47
Severe reversible toxic encephalopathy induced by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy. ( 17762922 )
2007
48
Cognitive functioning in patients with suspected chronic toxic encephalopathy: evidence for neuropsychological disturbances after controlling for insufficient effort. ( 16484635 )
2006
49
Visual search and eye movements in patients with chronic solvent-induced toxic encephalopathy. ( 16765447 )
2006
50
Taurine induced toxic encephalopathy? ( 16844286 )
2006

Variations for Toxic Encephalopathy

Expression for Toxic Encephalopathy

Search GEO for disease gene expression data for Toxic Encephalopathy.

Pathways for Toxic Encephalopathy

Pathways related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 APP BDNF GRIN2A GRIN2B MAOB SLC18A2
2
Show member pathways
13.36 APP BDNF CASP3 CYCS GRIN2A GRIN2B
3
Show member pathways
12.87 ACHE GRIN2A GRIN2B MAOB SLC18A2 SLC6A3
4 12.33 APP GRIN2A GRIN2B NGF PRNP SNCA
5 12.06 BDNF CASP3 NGF TH
6 11.98 BDNF CASP3 GRIN2B NGF
7 11.87 APP CASP3 MAOB SLC18A2
8
Show member pathways
11.84 CASP3 CYCS GRIN2A GRIN2B
9 11.64 CASP3 CYCS SLC6A3 SNCA TH
10 11.62 CASP3 CYCS GSTM1
11 11.56 ABCB1 ABCG2 HMOX1
12 11.47 APP CASP3 PRNP
13 11.45 ABCG2 BDNF NGF SLC18A2 TH
14
Show member pathways
11.35 ACHE SLC6A3 TH
15
Show member pathways
11.24 BDNF GRIN2A GRIN2B MAOB SLC18A2 SLC6A3
16 11.17 MAOB SLC6A3 SNCA TH
17
Show member pathways
11.17 APP BDNF CASP3 CYCS NGF
18 11.15 SLC18A2 SLC6A3 TH
19 10.97 ABCB1 CASP3 CYCS
20 10.75 MAOB TH
21 10.74 BDNF CASP3
22 10.71 ABCB1 ABCG2
23 10.66 ACHE TH

GO Terms for Toxic Encephalopathy

Cellular components related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.85 ACHE APP GRIN2A GRIN2B SNCA
2 neuron projection GO:0043005 9.72 APP GRIN2A GRIN2B SLC6A3 TH
3 membrane raft GO:0045121 9.67 APP CASP3 PRNP SLC6A3
4 axon GO:0030424 9.63 APP BDNF NGF SLC6A3 SNCA TH
5 cell surface GO:0009986 9.5 ABCB1 ACHE APP GRIN2A GRIN2B PRNP
6 dopaminergic synapse GO:0098691 9.43 SLC18A2 SLC6A3
7 terminal bouton GO:0043195 9.43 SLC18A2 SNCA TH
8 NMDA selective glutamate receptor complex GO:0017146 9.4 GRIN2A GRIN2B
9 synaptic vesicle GO:0008021 9.1 BDNF GRIN2A NGF SLC18A2 SNCA TH

Biological processes related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.98 GRIN2A GRIN2B SLC18A2 SNCA
2 positive regulation of apoptotic process GO:0043065 9.97 CASP3 GRIN2A HMOX1 NGF SNCA
3 response to lipopolysaccharide GO:0032496 9.89 CASP3 MAOB SNCA TH
4 negative regulation of neuron apoptotic process GO:0043524 9.86 BDNF HMOX1 NGF SNCA
5 response to wounding GO:0009611 9.84 ACHE CASP3 GRIN2A
6 excitatory postsynaptic potential GO:0060079 9.83 GRIN2A GRIN2B SNCA
7 modulation of chemical synaptic transmission GO:0050804 9.8 BDNF GRIN2A NGF
8 learning GO:0007612 9.79 APP GRIN2A TH
9 locomotory behavior GO:0007626 9.78 APP SLC18A2 SLC6A3 TH
10 long-term synaptic potentiation GO:0060291 9.76 GRIN2A GRIN2B SNCA
11 positive regulation of neuron death GO:1901216 9.72 GRIN2B PRNP SNCA
12 memory GO:0007613 9.71 BDNF GRIN2A NGF TH
13 dopamine metabolic process GO:0042417 9.7 GRIN2A SNCA
14 response to amphetamine GO:0001975 9.7 GRIN2A SLC18A2 TH
15 glutamate receptor signaling pathway GO:0007215 9.69 GRIN2A GRIN2B
16 cellular copper ion homeostasis GO:0006878 9.69 APP PRNP
17 nerve development GO:0021675 9.69 BDNF NGF
18 cellular response to amyloid-beta GO:1904646 9.69 APP GRIN2A PRNP
19 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.68 NGF SNCA
20 nerve growth factor signaling pathway GO:0038180 9.68 BDNF NGF
21 negative regulation of activated T cell proliferation GO:0046007 9.68 CASP3 PRNP
22 negative regulation of long-term synaptic potentiation GO:1900272 9.67 APP PRNP
23 neuron projection maintenance GO:1990535 9.67 APP PRNP
24 neurotransmitter catabolic process GO:0042135 9.67 ACHE MAOB
25 cellular response to copper ion GO:0071280 9.67 APP PRNP SNCA
26 cellular response to manganese ion GO:0071287 9.66 APP TH
27 monoamine transport GO:0015844 9.65 SLC18A2 SLC6A3
28 dopamine catabolic process GO:0042420 9.65 MAOB SLC6A3
29 excitatory chemical synaptic transmission GO:0098976 9.64 GRIN2A GRIN2B
30 mating behavior GO:0007617 9.64 APP TH
31 positive regulation of collateral sprouting GO:0048672 9.63 BDNF NGF
32 ionotropic glutamate receptor signaling pathway GO:0035235 9.63 APP GRIN2A GRIN2B
33 calcium ion transmembrane import into cytosol GO:0097553 9.61 GRIN2A GRIN2B
34 modulation of age-related behavioral decline GO:0090647 9.61 APP PRNP
35 neurotrophin TRK receptor signaling pathway GO:0048011 9.61 BDNF CASP3 NGF
36 dopamine transport GO:0015872 9.6 SLC18A2 SLC6A3
37 aminergic neurotransmitter loading into synaptic vesicle GO:0015842 9.57 SLC18A2 TH
38 response to nicotine GO:0035094 9.56 CASP3 HMOX1 SLC6A3 TH
39 response to ethanol GO:0045471 9.55 GRIN2A GRIN2B MAOB SLC6A3 TH
40 negative regulation of dendritic spine maintenance GO:1902951 9.54 GRIN2B PRNP
41 neurotransmitter biosynthetic process GO:0042136 9.54 ACHE SLC6A3 TH
42 dopamine biosynthetic process GO:0042416 9.5 SLC6A3 SNCA TH
43 learning or memory GO:0007611 9.35 APP CASP3 GRIN2A GRIN2B PRNP
44 xenobiotic transport GO:0042908 9.33 ABCG2
45 response to drug GO:0042493 9.23 ABCB1 ABCG2 CASP3 GRIN2A MAOB SLC6A3

Molecular functions related to Toxic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.63 CASP3 PRNP SLC6A3
2 ionotropic glutamate receptor activity GO:0004970 9.43 GRIN2A GRIN2B
3 dopamine binding GO:0035240 9.4 SLC6A3 TH
4 monoamine transmembrane transporter activity GO:0008504 9.37 SLC18A2 SLC6A3
5 enzyme binding GO:0019899 9.35 APP GSTM1 HMOX1 SNCA TH
6 NMDA glutamate receptor activity GO:0004972 9.32 GRIN2A GRIN2B
7 cuprous ion binding GO:1903136 9.26 PRNP SNCA
8 xenobiotic transmembrane transporting ATPase activity GO:0008559 8.85 ABCG2
9 glutamate-gated calcium ion channel activity GO:0022849 8.62 GRIN2A GRIN2B

Sources for Toxic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....